Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Eli Lilly and Company | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
In patients with type 2 diabetes, the incretin effect is markedly reduced contributing to the relative insulin deficiency that characterizes these patients. This defect is believed to be due to a decreased effect of GLP-1 and an almost ceased effect of GIP. Nevertheless, the impact of the defect on glucose tolerance is not fully understood. The so-called gastrointestinal-mediated glucose disposal (GIGD) is a measure of glucose handling, which includes the incretin effect, but also other factors affecting glucose disposal (e.g. glucagon secretion). Interestingly, patients with type 2 diabetes exhibit elevated plasma glucagon levels in the fasting state, and glucagon concentrations fail to decrease appropriately and may even increase in response to ingestion of glucose and show exaggerated increases after a mixed meal. With the current project the investigators wish to elucidate how this paradoxical glucagon response observed in patients with type 2 diabetes affects the GIGD, the incretin effect and postprandial glucose excursions.
Ten patients with type 2 diabetes and 10 healthy matched control subjects will be enrolled in this randomised, placebo-controlled, double-blinded study. The aim is to examine the effect of a glucagon receptor antagonist (GRA) on gastrointestinal-mediated glucose disposal (GIGD), incretin effect and postprandial glucose excursions in patients with type 2 diabetes and healthy controls. Participants will attend two oral glucose tolerance tests (OGTT), two isoglycaemic iv glucose infusion (IIGI) and two standardised liquid meals.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| T2D + OGTT + LY2409021 | Active Comparator | Type 2 diabetes patients + 50 oral glucose tolerance test 4 hours + the human antagonist of the glucagon receptor. |
|
| T2D + OGTT + placebo | Placebo Comparator | Type 2 diabetes patients + 50 oral glucose tolerance test 4 hours + placebo comparator to the human antagonist of the glucagon receptor. |
|
| T2D + IIGI + LY2409021 | Active Comparator | Type 2 diabetes patients + isoglycaemic iv glucose infusion + the human antagonist of the glucagon receptor. |
|
| T2D + IIGI + placebo | Placebo Comparator | Type 2 diabetes patients + isoglycaemic iv glucose infusion + placebo comparator to the human antagonist of the glucagon receptor. |
|
| T2D + MEAL + LY2409021 | Active Comparator | Type 2 diabetes patients + Standardised liquid meal + the human antagonist of the glucagon receptor. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| LY2409021 | Drug |
|
| Measure | Description | Time Frame |
|---|---|---|
| Differences in GIGD (%) | GIGD = Gastrointestinal glucose disposal. GIGD (%) = 100% × (glucoseOGTT-glucoseIIGI)/glucoseOGTT. | Comparison between experimental days with and without the glucagon receptor antagonist . The glucose disposal at time 240 minutes will be used. |
| Difference in postprandial glucose excursions | Difference in postprandial glucose excursions (measured as incremental (baseline substracted) area under the curve (AUC) values). | Area under the curve (AUC) time frame: 0, 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 105, 120, 150, 180, 210, 240 minutes. Comparison between experimental days with and without the glucagon receptor antagonist. |
| Measure | Description | Time Frame |
|---|---|---|
| Incretin effect | The incretin effect (100% × [β-cell secretory response to oral glucose tolerance test - intravenous β-cell secretory response]/β-cell secretory response to oral glucose tolerance test) | Insulin AUC time frame: 0,10, 20, 30, 50, 60, 70, 90, 105, 120, 150, 240 minutes. Comparison between experimental days with and without the glucagon receptor antagonist |
Not provided
Inclusion Criteria:
Patients with type 2 diabetes
Healthy subjects
Exclusion Criteria:
Patients with type 2 diabetes
Healthy subjects
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Center for Diabetes Research, Gentofte Hospital, Copenhagen University | Hellerup | DK-2900 | Denmark |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000601762 | adomeglivant |
| D005951 | Glucose Tolerance Test |
| ID | Term |
|---|---|
| D001774 | Blood Chemical Analysis |
| D019963 | Clinical Chemistry Tests |
| D019411 | Clinical Laboratory Techniques |
| D019937 | Diagnostic Techniques and Procedures |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| T2D + MEAL + placebo | Placebo Comparator | Type 2 diabetes patients + Standardised liquid meal + placebo comparator to the human antagonist of the glucagon receptor. |
|
| CTRL + OGTT + LY2409021 | Active Comparator | Healthy controls + 50 oral glucose tolerance test 4 hours + the human antagonist of the glucagon receptor. |
|
| CTRL + OGTT + placebo | Placebo Comparator | Healthy controls + 50 oral glucose tolerance test 4 hours + placebo comparator of the human antagonist of the glucagon receptor. |
|
| CTRL + IIGI + LY2409021 | Active Comparator | Healthy controls + isoglycaemic iv glucose infusion + the human antagonist of the glucagon receptor. |
|
| CTRL + IIGI + placebo | Placebo Comparator | Healthy controls + isoglycaemic iv glucose infusion + placebo comparator the human antagonist of the glucagon receptor. |
|
| CTRL + MEAL + LY2409021 | Active Comparator | Healthy controls + Standardised liquid meal + the human antagonist of the glucagon receptor. |
|
| CTRL + MEAL + placebo | Placebo Comparator | Healthy controls + Standardised liquid meal + placebo comparator of the human antagonist of the glucagon receptor. |
|
| LY2409021 placebo | Drug |
|
| OGTT | Procedure |
|
| IIGI | Procedure |
|
| Standardised liquid meal | Procedure |
|
| Endogenous glucose production | Glucose rate of appearance will be calculated by the non-steady state equation using double tracer technique. | Plasma concentration of 6,6^2 H2-glucose and U-13C^6-glucose at times: 0,10, 20, 30, 50, 60, 70, 90, 105, 120, 150, 240 minutes. |
| Lipolysis | Glycerol disappearance will be calculated by the non-steady state equation using double tracer technique. | Plasma concentration of 1,1,2,3,3-^2-H5 - glycerol measured at times: 0,10, 20, 30, 50, 60, 70, 90, 105, 120, 150, 240 minutes. |
| Serum/plasma concentrations of insulin, C-peptide, glucagon, GIP and GLP-1. | Insulin, C-peptide, glucagon, GIP and GLP-1 serum/plasma concentrations will be measured in pM. | Time frame: 0,10, 20, 30, 50, 60, 70, 90, 105, 120, 150, 240 minutes. |
| Appetite | Appetite will be evaluated with a visual analogue scale (VAS). | VAS scales will be handed out at time 0, 30, 60, 90, 120, 150, 180 and 240 minutes. |
| Energy intake (kcal/kJ) | At the end of the clamp experiment food intake will be examined with an ad libitum meal. The weight of the food will be measured i grams and calculated to the energy intake in kcal/kJ. | At time 240 to 270, the participants will eat an ad libitum meal. Comparison between experimental days with and without the glucagon receptor antagonist |
| Changes in blood pressure (mmHg) | Measured at time 0 and time 210 minutes. Comparison between experimental days with and without the glucagon receptor antagonist |
| Changes in pulse rate (beat per minute) | Measured at time 0 and at time 210 minutes. Comparison between experimental days with and without the glucagon receptor antagonist |
| Differences in gastric emptying | Measurement of p-paracetamol. Measurement of time to peak and incremental area under the curve (iAUC) | -30,-15, 0, 10, 20, 30, 50, 70, 90, 105, 120, 150, 240 minutes |
| Free fatty acids | serum values of free fatty acids | -30,-15, 0, 10, 20, 30, 50, 70, 90, 105, 120, 150, 240 minutes |
| Fibroblast growth factor-21 | plasma values of FGF-21 | -30,-15, 0, 10, 20, 30, 50, 70, 90, 105, 120, 150, 240 minutes |
| D004700 | Endocrine System Diseases |
| D003933 | Diagnosis |
| D003940 | Diagnostic Techniques, Endocrine |
| D008919 | Investigative Techniques |